Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development.
Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development.
复制标题
DOI：
10.14740/wjon610w
复制
发表时间：
2015-03
影响因子：
5.2
通讯作者：
Huang CY
中科院分区：
文献类型：
--
作者：
Liu MT;Chen MK;Huang CC;Huang CY
本研究的目的是评估分子生物标志物的预后意义，为鼻咽癌（NPC）更准确的预后和开发新的治疗策略提供信息。鼻咽癌是一种独特的头颈部恶性上皮癌，与eb病毒（EBV）密切相关。目前对鼻咽癌预后的预测主要基于临床TNM分期；但同一临床分期的鼻咽癌患者往往表现出不同的临床结局，提示TNM分期不足以准确预测该病的预后。本文就分子标记物在鼻咽癌中的预后价值作一综述，并讨论鼻咽癌靶向治疗的潜在策略。在异常增殖信号通路（如Wnt/β-catenin通路）、细胞内有丝分裂信号畸变（如缺氧诱导因子(HIF)-1α）、受体介导畸变（如血管内皮生长因子（VEGF））、肿瘤抑制因子（如p16和p27活性）、细胞周期畸变（如细胞周期蛋白D1和细胞周期蛋白E）、细胞粘附畸变（如E-cadherin）中发挥作用的分子生物标志物；细胞凋亡失调（如survivin）和着丝粒畸变（着丝粒蛋白H）是鼻咽癌的预后标志物。血浆EBV DNA浓度和EBV编码的潜伏膜蛋白也是鼻咽癌的预后指标。讨论了分子靶向治疗鼻咽癌的意义。这种疗法可能与不同的细胞毒性药物联合使用，以对抗和根除肿瘤细胞。为了进一步提高局部-区域晚期鼻咽癌患者的总体生存率，需要开发包括预后分子标志物和分子靶向药物在内的创新策略。
The aim of the study was to evaluate the prognostic significance of molecular biomarkers which could provide information for more accurate prognostication and development of novel therapeutic strategies for nasopharyngeal carcinoma (NPC). NPC is a unique malignant epithelial carcinoma of head and neck region, with an intimate association with the Epstein-Barr virus (EBV). Currently, the prediction of NPC prognosis is mainly based on the clinical TNM staging; however, NPC patients with the same clinical stage often present different clinical outcomes, suggesting that the TNM stage is insufficient to precisely predict the prognosis of this disease. In this review, we give an overview of the prognostic value of molecular markers in NPC and discuss potential strategies of targeted therapies for treatment of NPC. Molecular biomarkers, which play roles in abnormal proliferation signaling pathways (such as Wnt/β-catenin pathway), intracellular mitogenic signal aberration (such as hypoxia-inducible factor (HIF)-1α), receptor-mediated aberrations (such as vascular endothelial growth factor (VEGF)), tumor suppressors (such as p16 and p27 activity), cell cycle aberrations (such as cyclin D1 and cyclin E), cell adhesion aberrations (such as E-cadherin), apoptosis dysregualtion (such as survivin) and centromere aberration (centromere protein H), are prognostic markers for NPC. Plasma EBV DNA concentrations and EBV-encoded latent membrane proteins are also prognostic markers for NPC. Implication of molecular targeted therapies in NPC was discussed. Such therapies could have potential in combination with different cytotoxic agents to combat and eradicate tumor cells. In order to further improve overall survival for patients with loco-regionally advanced NPC, the development of innovative strategies, including prognostic molecular markers and molecular targeted agents is needed.